Viking Therapeutics, Inc. (LON:0VQA)
38.67
+1.33 (3.55%)
At close: Aug 12, 2025
Viking Therapeutics Employees
Viking Therapeutics had 36 employees as of December 31, 2024. The number of employees increased by 9 or 33.33% compared to the previous year.
Employees
36
Change (1Y)
9
Growth (1Y)
33.33%
Revenue / Employee
n/a
Profits / Employee
-2.56M GBP
Market Cap
3.32B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 36 | 9 | 33.33% |
Dec 31, 2023 | 27 | 6 | 28.57% |
Dec 31, 2022 | 21 | 3 | 16.67% |
Dec 31, 2021 | 18 | -2 | -10.00% |
Dec 31, 2020 | 20 | 1 | 5.26% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
Oxford Nanopore Technologies | 1,382 |
HUTCHMED (China) | 1,811 |
Viking Therapeutics News
- 6 days ago - Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors - Benzinga
- 12 days ago - Is Viking Therapeutics the Next Big Biotech Bet? - The Motley Fool
- 19 days ago - Behind the Scenes of Viking Therapeutics's Latest Options Trends - Benzinga
- 19 days ago - Viking Therapeutics Q2: Confidently Continuing The Recovery - Seeking Alpha
- 20 days ago - Viking Therapeutics outlines Phase III VANQUISH trial enrollment of 5,600 patients while advancing oral obesity program - Seeking Alpha
- 20 days ago - Viking Therapeutics, Inc. (VKTX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Viking Therapeutics Posts Wider Q2 Loss - The Motley Fool
- 21 days ago - Viking Therapeutics EPS miss sends shares down 7% - Seeking Alpha